Chris Schott

Can you just comment a little bit on what dosing looks like for this combo and where you see this fitting into the competitive landscape

how you think about sustaining the competitive position you have in I&I how important the Skyrizi combo is, your ability, again, freedom to operate with BD

is that the case in both Crohn's and UC, or is that just more a holistic kind of IBD comment

with the TREMFYA subcu induction dosing kind of rolling out, what are you seeing in terms of competitive dynamics and positioning

specifically, is it all IBD? Or are you also seeing upside to the derm indications as well

Can you talk a bit more about how you're thinking about the tail for Humira in light of some of the erosion that you're seeing this year

Can you just elaborate a little bit more on which of the indications are most attributable to the upside we're seeing right now

how we should think about the growth rate beyond 2027? So basically, how mature will these franchises be by then

can you just elaborate on what were the biggest drivers of upside to those targets, as you think about the various indications

Are you able to provide any more color on what levels of vomiting and duration of vomiting you are seeing with the three-step titration

as you're thinking about just pushing the program beyond monthly, what profile do you think you'd need to see for that to have a role in the market? Are there minimum efficacy bars you're looking at?

I'd just be interested in just Amgen's latest view on kind of the obesity market and the company's role within the market with MariTide and the broader pipeline.

can you just talk a little bit about the bar that you see here in terms of what we see from that data to be clinically meaningful?

I'm just interested and how you're thinking about these payer dynamics, potential new entrants in that space over time?

can you talk about ex U.S., the Japan opportunity and some of these new markets? And can we think about the rapid ramp that we saw in the U.S. kind of repeating itself

on the earlier stage pipeline, just elaborate a little bit more on your priorities here

I just would love a bit more elaboration on latest thoughts on business development in terms of the size and scopes of deals you're considering

is this kind of $3.9 billion or so OpEx space, a good rough number to think about for Biogen going forward?

Can you just elaborate a little bit more the role in the market you see for those products based on these initial data sets

can you just talk about Camzyos potential post your competitor approval? Just what are you seeing in the market

just elaborate on Eliquis dynamics for 2026 contributing to growth this year

Should we think about Bristol-Myers Squibb Company waiting to see how these programs pan out and that that might help guide where you wanna go with BD, or is that not a rate limiter for the company

can you just talk about the relative confidence you have in those studies relative to ADEPT-2, just given some of the differences in study designs

what you see as the primary hurdles to adoption for physicians at this point given reimbursement, et cetera, in place

can you just provide any color on the company's US manufacturing footprint ability to shift manufacturing to US over time

Talk a little bit about what this does for your outlook on Cobenfi

Can you just elaborate on how you're thinking about the ramp of the drug from here

should we think about additional cost opportunities as you go through that 2028 LOE cycle

do you think you are going to need the second-line IMagine-3 data before you can broadly convert over practices

Can you just elaborate a little bit more on the assumptions driving the $800 million guidance

I'm just trying to understand a little bit more about how you're envisioning the shape of the curve. Is this kind of like a gradual acceleration or a bigger step function as we move into 2026

just elaborate on your confidence on the 4182, 1720, the weekly treatment combo, the WONDERS program following the clinical hold

what you're seeing from a competitive standpoint and how that ramp is progressing relative to your internal expectations

how much of this is commercial execution on IDEXX's part versus just maybe healthier broader market trends

elaborate a little bit more on how that initial utilization and uptake has ramped relative to your expectations

how you're thinking about this evolving in 2026 as we think about wellness versus non-wellness visits in that negative two percent overall number

is it fair to think about this point this now being a tailwind for the business as we look out to 2026 and beyond and start thinking about [ positive ] at least clinical visit growth

what type of practices are you seeing the greatest amount of traction here

can you just elaborate on the vet visit trajectory you expect from here?

Any notable kind of differences or trends that you're expecting as we think about the regions?

you mentioned 1,500 prescriptions so far. Is there any color on where those customers are coming from

should we think about this as a similar dynamic to TREMFYA that skews more towards IBD versus psoriasis

Should we think about that higher level of top-line growth being associated with greater margin expansion? Or is this kind of 50 basis point year type improvement you're seeing this year a reasonab...

Can you just talk about how you're thinking about MFN tariffs, etcetera

any color you might hire up in terms of the drivers of upside to the guidance for the year

I think you mentioned in the remarks about 150 basis points of improvement this year in process R&D

I just wanted to dig a little bit more into international Mounjaro

Just interested in your thoughts on the ramp from here as we think about the $3.3 billion 4Q result you just reported

Can you just elaborate a little bit more on how some of these new country launches are trending relative to your expectations? How to think about growth off of this new higher base

Can you just help put the data into context and just, in general, your thinking of where orfo fits into the treatment landscape versus Zepbound and Wegovy

can you just elaborate a bit more on the role you see orforglipron playing in the core obesity and diabetes market relative to injectables?

can you just talk a little bit about the role you're seeing TL1A playing in the IBD space

what gives you such confidence in this asset and how large of an opportunity you see assuming we get some positive data

should we be thinking about this type of structure as a reasonable framework for the industry

how we should think about either operating margins or absolute OpEx growth trending in the next few years

can you just talk about GARDASIL and the potential to move to a single dose in The US

I guess just given the Vyndamax clarity, could the company look at larger transactions if the right deal were to present itself?

Can you just talk generally about the business trends versus your expectations and just how you're thinking about the year progressing from here?

can you just elaborate any more on the tolerability you saw here? And maybe specifically, anything more you can say about vomit rates or any differences you saw between the mild or moderate dosing ...

if we consider the two doses that are moving forward from VSPR-three, it seems like you have a drug that clearly has solid weight loss. Got monthly dosing

trying to get a little bit more color on the MFN impact for 2026. I think you mentioned some dilution there

As you think about MFN on new launches over time, what do you think about this suggesting for international revenues

what's driving the slightly lower target leverage for the company going forward?

Will we need to see the Phase III data from those ADCs before you move forward?

should we still think about full-year gross margins in the mid-seventies range or has that changed at all following some of the upside with 1Q?

Can you talk a little bit about the thinking on the size of the opportunity from here and the potential for growth

Can you just help size the range of what Pfizer is able to look at from here and how you think about balancing business development versus share repo

how is that progressing versus expectations? And can you just elaborate a bit on the time lines

beyond the manufacturing dynamics, is there anything else pending with these three filings based on your discussion

any updated thoughts on when we could think about the foundation reopening

generic semaglutide beginning to enter in some specific markets. Just wondering if there's any learnings

is that a good proxy to think about for underlying growth before we consider some of these bigger pipeline readouts in BD

any more color you can provide on the quantum of expense reduction we should be thinking about here

Can you just help us frame out how you're thinking about the peak sales opportunity and kind of the ramp once approved for this drug

for the 50% of your sales in the U.S. that aren't manufactured domestically, how should we think about the company's ability to mitigate

can you just elaborate on the scope, maybe size and timing of the enterprise review you mentioned on the call

How much of that's coming from Indore and how much of that's coming from some other factors that you cited

do you think this is a business that can kind of get back to flat or growing as we go through the year

Is that something you're reacting to on price on your side? Or is that more -- we should be thinking about share loss

Can you just elaborate a little bit more in terms of what your outlook of when we could see that recovery

you've now moved to about 45% share in vet practices for triples. I was just curious in terms of where you think that market can go over time

Can you just remind us of your latest expectations for Merck’s entrance into the market? What’s kind of reflected in guidance on that?

Is there any updates in terms of how you're seeing veterinarians approach patient selection as you think about severe patients versus moderate?

Just any pushes and pulls we should think about for that product specifically in '25?